Israel-based Novoxel announced the FDA clearance of its Tixel device for the application of localized heat and pressure for patients who have evaporative dry eye disease due to meibomian gland dysfunction (MGD).

The Tixel system uses proprietary Thermo-Mechanical Action (TMA) instead of light or laser energy. This allows the device to be used on all skin tones, all year round, according to Novoxel. The TMA technology permits treatment of the glands in both the upper and lower eyelids to help improve delivery of lubricating oils to the eye surface.

All US sales, marketing, and technical support for the Tixel family of products will be handled at Noxoxel’s Tennessee facility.